Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.

Original languageEnglish
Pages (from-to)1137-1146
Number of pages10
JournalPharmacotherapy
Volume24
Issue number9
DOIs
StatePublished - Sep 4 2004

Fingerprint

Patient Acceptance of Health Care
Health Resources
Brain Natriuretic Peptide
Heart Failure
Length of Stay
Patients' Rooms
State Hospitals
Critical Care
Routine Diagnostic Tests
Hypotension
Atrial Fibrillation
Case-Control Studies
Cardiac Arrhythmias
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{250974ba388c44bbb0c564c94f7b91fe,
title = "Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure",
abstract = "Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.",
author = "Lenz, {Thomas L.} and Foral, {Pamela A.} and Malesker, {Mark A.} and Hunter, {Claire B.} and Hilleman, {Daniel E.}",
year = "2004",
month = "9",
day = "4",
doi = "10.1592/phco.24.13.1137.38081",
language = "English",
volume = "24",
pages = "1137--1146",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "9",

}

TY - JOUR

T1 - Impact of nesiritide on health care resource utilization and complications in patients with decompensated heart failure

AU - Lenz, Thomas L.

AU - Foral, Pamela A.

AU - Malesker, Mark A.

AU - Hunter, Claire B.

AU - Hilleman, Daniel E.

PY - 2004/9/4

Y1 - 2004/9/4

N2 - Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.

AB - Study Objective. To determine the impact of nesiritide on health care resource utilization and complications in patients hospitalized with decompensated heart failure. Design. Retrospective case-control study. Setting. United States hospitals. Patients. Two hundred sixteen patients hospitalized for decompensated heart failure. Measurements and Main Results. One hundred eight patients who received a nesiritide infusion for a minimum of 12 hours during the first 48 hours after hospital admission were matched with 108 patients not receiving nesiritide. Health care resource utilization, consisting of hospital length of stay (LOS), rate of rehospitalization within 90 days, concomitant drugs administered, and laboratory and diagnostic tests, was determined for each hospital admission. Rates of adverse events also were recorded. Patients receiving nesiritide had a significantly shorter LOS in a critical care unit (p=0.03). General medical ward or step-down unit LOS was not different between the treatment groups. A favorable trend toward a lower rate of rehospitalization over the 90-day follow-up period was observed with nesiritide (p=0.07). The number of patients who developed life-threatening ventricular arrhythmias and hypotension was similar for both treatment groups. However, in patients receiving nesiritide, significantly less atrial fibrillation (p=0.03) and renal dysfunction (p=0.04) occurred compared with patients not receiving nesiritide. Conclusion. Nesiritide therapy is associated with significant reductions in both health care resource utilization and complications in patients with decompensated heart failure.

UR - http://www.scopus.com/inward/record.url?scp=4344612205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344612205&partnerID=8YFLogxK

U2 - 10.1592/phco.24.13.1137.38081

DO - 10.1592/phco.24.13.1137.38081

M3 - Article

C2 - 15460174

AN - SCOPUS:4344612205

VL - 24

SP - 1137

EP - 1146

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 9

ER -